|
rs7939734
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The AT or TT genotype of rs7939734 in Fas-associated protein with death domain (FADD) was associated with increased risk of childhood leukemia compared with the AA genotype (odds ratio [OR] = 2.26, 95% confidence interval [95% CI] = 1.20-4.25, p(trend) = 0.0007, min p = 0.002, false discovery rate [FDR] p = 0.17).
|
22244917 |
2012 |
|
rs974120
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The locus of rs974120 shows marks of transcriptional activity in leukemia according to ENCODE data. rs10251201 (7p21.3), rs9318227 (13q22.1), and rs10405859 (19q13.32) were associated with markers related to leukemogenesis and immune and inflammatory responses.
|
28375557 |
2017 |
|
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These findings provide further evidence that the MDR1 C3435T variant may modify the susceptibility to leukemia.
|
22088099 |
2012 |
|
rs2032582
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results suggested that there was no association between MDR1 G2677T polymorphism and leukemia risk in overall populations, but significant association was found in others populations (Asians and Africans), and myeloid leukemia indicated that G2677T polymorphism might be a protective factor in the susceptibility of myeloid leukemia and in Asians and Africans.
|
24142546 |
2014 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
One mutation, T315I, for example, renders the leukemia resistant to all first- and second-line TKIs.
|
23666688 |
2013 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
|
28810255 |
2017 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system.
|
29967475 |
2018 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In BCR/ABL- or BCR/ABL-T315I-driven murine leukemia as well as in xenograft models of primary Ph+ leukemia harboring the T315I, PF-114 significantly prolonged survival to a similar extent as ponatinib.
|
25394714 |
2015 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph(+)) leukemia, including the recalcitrant BCR-ABL1(T315I) mutant.
|
25132497 |
2014 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
|
29321163 |
2018 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.
|
22985168 |
2012 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Collectively, the present results suggest that in the treatment of leukemia, taxodione has potential as a compound with high efficacy to overcome BCR-ABL T315I mutation-mediated resistance in leukemia cells.
|
29859988 |
2018 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
|
22772060 |
2013 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although many imatinib-resistant mutations respond well to second-generation TKIs, the threonine-to-isoleucine mutation at codon 315 of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion Bcr-Abl (T315I) is insensitive to all currently available TKIs.
|
20564073 |
2010 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Surprisingly, inhibition of AurA by AKI603 induced leukemia cell senescence in both BCR-ABL wild type and T315I mutation cells.
|
27824120 |
2016 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients.
|
19541823 |
2009 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although strategies to overcome resistance-mediated T315I mutation may improve the survival of BCR-ABL-positive leukemia patients, there is little information on cell-based studies.
|
20471447 |
2010 |
|
rs121913452
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance.
|
25379619 |
2015 |
|
rs121913461
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We conclude that patients with Ph+ leukemia with Y253H or F359V mutation have a high likelihood of developing new mutations in the setting of dasatinib resistance.
|
25379619 |
2015 |
|
rs10508293
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The maternal methylenetetrahydrofolate reductase A1298C polymorphism was found to be an effect modifier of the maternal intron 4 polymorphism of the AKR1C3 gene (rs10508293) and the childhood leukemia risk.
|
18339682 |
2008 |
|
rs121434592
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Recently, the E17K mutation in the AKT1 has been associated with multiple human malignancies and leukemia in mice.
|
20440266 |
2010 |
|
rs121434592
|
|
|
0.020 |
GeneticVariation |
BEFREE |
They described a novel point mutation (E17K) in the pleckstrin homology domain (PHD) of the AKT1 gene in human breast, colorectal and ovarian cancers, and demonstrated that it induces leukemia in mice.
|
17921701 |
2007 |
|
rs387906659
|
|
|
0.010 |
GeneticVariation |
BEFREE |
They described a novel point mutation (E17K) in the pleckstrin homology domain (PHD) of the AKT1 gene in human breast, colorectal and ovarian cancers, and demonstrated that it induces leukemia in mice.
|
17921701 |
2007 |
|
rs10931910
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found a significant decrease in clearance (τ=-0.32, P=0.003) in solid tumor patients with rs10931910, although it failed to replicate in the leukemia cohort (τ=0.18, P=0.20).
|
24300566 |
2014 |
|
rs1130409
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Progression to secondary myelofibrosis/leukemia is influenced by exposure to cytoreductive agents, and caspase and BER polymorphisms {globally, CASP8 3'untranslated region [odds ratio (OR)=0.24; 95% confidence interval (CI), 0.08‑0.69], XRCC1 Arg194Trp [OR=3.58; 95% CI, 0.98‑13.01]; for essential thrombocythemia patients CASP9 Arg173His [OR=11.27; 95% CI, 1.13‑112.28], APEX1 Asp148Glu [OR=0.28; 95% CI, 0.74‑1.03], and XRCC1 Arg194Trp [OR=6.60; 95% CI, 1.60‑27.06]}.
|
30320340 |
2018 |